BIOPHARMA
By
Can Takeda and Nabla Bio’s $1 Billion AI Alliance Redefine the Future of Protein Therapeutics?
Key Highlights: AI Takes Center Stage in Takeda’s R&D RebootAfter narrowing its research focus to small molecules, biologics,…
Could Cohere’s New Paris Office Accelerate AI Adoption Across Europe’s Healthcare and Biopharma Sector?
Key Insights: Expanding Footprint in Europe Cohere, a Canadian AI firm known for developing large language models and…
Can GHX’s AI-Driven Supply Chain Solutions Transform How Hospitals Tackle Disruptions?
Key Highlights AI reshaping healthcare supply chains: Unlike retail or tech, healthcare requires flawless delivery—any delay can directly…
Is Stanford’s MedAgentBench Setting the New Gold Standard for AI in Clinical Care?
Key Highlights AI benchmarking moves beyond knowledge tests: Unlike earlier evaluations that focused on exams like the USMLE,…
U.S. FDA Approves JASCAYD® for Progressive Pulmonary Fibrosis – A New Treatment Option for Adults?
Boehringer Ingelheim announced that the U.S. Food and Drug Administration (FDA) has approved JASCAYD® (nerandomilast) tablets for the…
Are Galux and Boehringer Ingelheim Pioneering AI in Precision Protein Design?
December 17, 2025 — Galux, a South Korean biotech company focused on AI-driven protein therapeutics, has entered a…
